Naturhouse Health (NTH) AI Stock Analysis

• Market Cap: €135.49M
• Dividend Yield: 7.35%
• Average Volume (3M): 72.19K
• Price to Earnings (P/E): 13.2
• Beta (1Y): 0.21
• Revenue Growth: -4.18%
• EPS Growth: 4.98%
• Country: ES
• Employees: 191
• Sector: Healthcare
• Sector Strength: 45
• Industry: Packaged Foods
• EPS (TTM): 0.16
• Shares Outstanding: 60,000,000
• 10 Day Avg. Volume: 152,933
• 30 Day Avg. Volume: 72,194
• PEG Ratio: -0.64
• Price to Book (P/B): 3.14
• Price to Sales (P/S): 2.01
• P/FCF Ratio: 8.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.50
• Price Target Upside: 9.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: €2.50 ▲(9.65% Upside)

Naturhouse Health's stock is supported by strong technical indicators and an attractive valuation, with a reasonable P/E ratio and high dividend yield. However, concerns about declining revenue and free cash flow growth weigh on the overall score. The stock's bullish momentum is tempered by overbought signals, suggesting potential short-term volatility.

Naturhouse Health Business Overview & Revenue Model

Company Description

Naturhouse Health, S.A. operates in the nutrition and weight management industry in Spain, Italy, France, Poland, and internationally. The company sells food supplements that are made from natural extracts to facilitate the consumption of various nutrients; and foods and drinks, such as diet products for breakfast, snacks, and meal substitutes. It also offers cosmetics and body care products, including beauty products related to skincare during the slimming process comprising cellulite, firming products, etc.; and anti-ageing products. As of December 31, 2020, it operated through a network of 1,788 centers in 28 countries. The company sells its products through directly operated and franchised Naturhouse centers. The company was formerly known as Housediet, S.L.U. The company was founded in 1991 and is based in Madrid, Spain.

How the Company Makes Money

Naturhouse Health generates revenue primarily through its franchise operations, where franchisees pay initial setup fees and ongoing royalties based on their sales. Additionally, the company earns money by selling its proprietary nutritional products and supplements directly to both franchisees and customers. A significant portion of its earnings also comes from strategic partnerships with health professionals and wellness centers, which help to expand its reach and credibility in the market. The company's continued investment in marketing and brand development further enhances its revenue potential by attracting new customers and retaining existing ones.

Naturhouse Health Financial Statement Overview

Summary

Naturhouse Health shows strong profitability with high gross and net profit margins, and a robust equity position. However, declining revenue and free cash flow growth are significant concerns that need addressing for long-term sustainability.

Income Statement

Naturhouse Health's income statement reflects a mixed performance. The company has maintained strong gross profit margins consistently above 70%, indicating efficient cost management. However, the revenue has been declining over the years, with a significant drop in 2024. The net profit margin remains healthy at around 20%, but the declining revenue growth rate is a concern. EBIT and EBITDA margins are stable, but the overall revenue trajectory needs improvement.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, indicating financial stability and low leverage risk. Return on equity is robust, reflecting effective use of equity to generate profits. The equity ratio is healthy, suggesting a solid financial foundation. However, the declining total assets over the years could be a potential risk if not addressed.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth, which is concerning. The operating cash flow to net income ratio is strong, indicating good cash generation relative to net income. However, the negative free cash flow growth rate in recent years highlights potential challenges in maintaining cash reserves. The company needs to focus on improving cash flow generation to support future growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.42M	50.41M	52.40M	57.59M	55.08M
Gross Profit	35.46M	25.11M	37.48M	41.26M	38.97M
EBITDA	15.63M	17.93M	15.61M	20.80M	16.96M
Net Income	9.86M	11.29M	9.63M	13.36M	9.38M
Balance Sheet
Total Assets	42.59M	48.85M	42.82M	49.00M	42.58M
Cash, Cash Equivalents and Short-Term Investments	21.67M	27.10M	14.78M	27.25M	21.61M
Total Debt	3.04M	5.05M	3.27M	2.23M	3.69M
Total Liabilities	10.91M	18.21M	14.96M	12.92M	16.55M
Stockholders Equity	31.68M	30.63M	27.81M	36.02M	25.96M
Cash Flow
Free Cash Flow	11.22M	20.38M	6.13M	16.12M	14.38M
Operating Cash Flow	11.56M	20.95M	7.10M	16.17M	14.58M
Investing Cash Flow	862.00K	-459.00K	-5.22M	-4.27M	112.00K
Financing Cash Flow	-16.10M	-7.70M	-16.98M	-6.27M	-3.39M

Naturhouse Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:NTH, the sentiment is Positive. The current price of 2.28 is above the 20-day moving average (MA) of 2.06, above the 50-day MA of 1.97, and above the 200-day MA of 1.74, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 77.82 is Negative, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:NTH.

Naturhouse Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTH	73 Outperform	€135.49M	13.25	38.28%	7.35%	-4.18%	4.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%